EP Patent

EP2211870A1 — Cytidine analogs for treatment of myelodysplastic syndromes

Assigned to Celgene International SARL · Expires 2010-08-04 · 16y expired

What this patent protects

The present invention provides methods of treating a patient having a higher risk myelodysplastic syndrome, which comprises administering to a patient having a higher risk myelodysplastic syndrome a therapeutically effective amount of a cytidine analog. The cytidine analog includ…

USPTO Abstract

The present invention provides methods of treating a patient having a higher risk myelodysplastic syndrome, which comprises administering to a patient having a higher risk myelodysplastic syndrome a therapeutically effective amount of a cytidine analog. The cytidine analog includes 5 -aza-2'-deoxy cytidine, 5-azacytidine, 5-aza-2'-deoxy- 2',2'-difluorocytidine, 5-aza-2'-deoxy-2'-fluorocytidine, 2'-deoxy-2',2'-difluorocytidine, cytosine 1-β-D-arabinofuranoside, 2(1H) pyrimidine riboside, 2'-cyclocytidine, arabinofuanosyl-5-azacytidine, dihydro-5-azacytidine, N4-octadecyl-cytarabine, and elaidic acid cytarabine

Drugs covered by this patent

Patent Metadata

Patent number
EP2211870A1
Jurisdiction
EP
Classification
—
Expires
2010-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Celgene International SARL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.